Male breast cancer with mandibular metastasis. A case report

Minerva Stomatol. 2007 Apr;56(4):225-30.
[Article in English, Italian]

Abstract

Female breast cancer is one of the major causes of death among women while male breast cancer is relatively uncommon and accounts for about 1% of all breast cancers in both sexes. Influencing factors are: gynecomasty, familiarity for male breast cancer, Jewish and African-American male population. From the histological point of view, it is not different from the female breast cancer, except for the infiltrant ductal carcinoma, but with a much severe prognosis. Breast cancer metastases to the jaws are rare, only 1%; the most common sites of metastases are: lungs(59-69%), liver (58-65%), bone (44-71%), pleura (23-37%), brain (9-22%) and kidney (4-17%). At present, based on a literature research (May 2006), there have been just two other case reports of male breast cancer metastasis to the maxillofacial region, both to the mandible. The case of a 69-year-old white man who in 2001 underwent a radical mastectomy due to ductal breast cancer is reported. In 2005 the patient was referred to our department by his oncologist for multiple oral fistula. A mandibular TC revealed osteolytic lesions and the patient underwent mandibular surgery to remove the lesions and clean up the area. The histological examination was consistent with that of a metastatic deposit of adenocarcinoma of the breast. In June 2006 the patient died due to worsening of the general clinical conditions, in particular due to ascites and hepatic insufficiency.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Androstadienes / administration & dosage
  • Antimetabolites, Antineoplastic / therapeutic use
  • Antineoplastic Agents, Hormonal / therapeutic use
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Antineoplastic Combined Chemotherapy Protocols / therapeutic use*
  • Bone Density Conservation Agents / therapeutic use
  • Bone Neoplasms / radiotherapy
  • Bone Neoplasms / secondary
  • Brain Neoplasms / radiotherapy
  • Brain Neoplasms / secondary
  • Breast Neoplasms, Male / drug therapy
  • Breast Neoplasms, Male / pathology*
  • Breast Neoplasms, Male / surgery
  • Carcinoma, Ductal, Breast / drug therapy
  • Carcinoma, Ductal, Breast / secondary*
  • Carcinoma, Ductal, Breast / surgery
  • Cortisone / administration & dosage
  • Cyclophosphamide / administration & dosage
  • Diphosphonates / therapeutic use
  • Docetaxel
  • Fatal Outcome
  • Fluorouracil / administration & dosage
  • Furosemide / therapeutic use
  • Humans
  • Imidazoles / therapeutic use
  • Liver Neoplasms / drug therapy
  • Liver Neoplasms / secondary
  • Male
  • Mandibular Neoplasms / drug therapy
  • Mandibular Neoplasms / secondary*
  • Mandibular Neoplasms / surgery
  • Mastectomy, Modified Radical
  • Methotrexate / administration & dosage
  • Omeprazole / administration & dosage
  • Osteolysis / drug therapy
  • Osteolysis / etiology
  • Phenobarbital / administration & dosage
  • Taxoids / administration & dosage
  • Toremifene / therapeutic use
  • Vinblastine / analogs & derivatives
  • Vinblastine / therapeutic use
  • Vinorelbine
  • Zoledronic Acid

Substances

  • Androstadienes
  • Antimetabolites, Antineoplastic
  • Antineoplastic Agents, Hormonal
  • Bone Density Conservation Agents
  • Diphosphonates
  • Imidazoles
  • Taxoids
  • Docetaxel
  • Vinblastine
  • Zoledronic Acid
  • Furosemide
  • Toremifene
  • Cyclophosphamide
  • Omeprazole
  • exemestane
  • Vinorelbine
  • Fluorouracil
  • Cortisone
  • Methotrexate
  • Phenobarbital

Supplementary concepts

  • CMF regimen